Introduction
Primary biliary cholangitis (PBC) is a rare, progressive autoimmune liver disease that gradually damages the small bile ducts within the liver. Over time, impaired bile flow can lead to inflammation, scarring, and declining liver function. Although ursodeoxycholic acid (UDCA) remains the standard first-line treatment, some patients do not achieve an adequate response or cannot tolerate the medication.
Iqirvo is a prescription oral therapy approved for adults with primary biliary cholangitis. It may be used together with UDCA in patients whose disease has not responded adequately to UDCA alone or as monotherapy for patients who are unable to tolerate UDCA. By activating two receptors involved in bile acid metabolism and inflammation, Iqirvo helps improve important laboratory markers associated with liver disease.
As a specialty medication for a rare liver disorder, Iqirvo can be expensive without adequate insurance coverage or financial assistance. Many patients searching for the Iqirvo patient assistance program are looking for ways to reduce out-of-pocket treatment costs while maintaining access to therapy.
Prescription Hope offers patients access to affordable medications for a simple service rate of $70.00 per month, per medication.
What Is the Iqirvo Patient Assistance Program?
Understanding Iqirvo Prescription Assistance
While looking for help paying for Iqirvo, some patients may have seen the Iqirvo patient assistance program. But what is it?
Pharmaceutical manufacturers recognize the financial burden that some name-brand medications can cause for American patients. To help, manufacturers often launch patient assistance programs, which allow qualified patients access to the name-brand medication they need at a fraction of the retail cost.
However, some programs typically require extensive documentation, research, and communication with healthcare providers and the manufacturer. All of that paperwork on top of seeking out treatment for their condition can cause a sense of overwhelm and frustration.
Prescription Hope wants to help.
How Expert Advocates Help Make Iqirvo More Affordable
Personalized Medication Assistance
Prescription Hope’s Iqirvo enrollment assistance helps patients receive the name-brand medication they need at a lower cost than market price.
Our team of patient advocates provides compassionate patient support services. We help you complete your prescription assistance program by taking care of forms, documents, and signatures, communication with healthcare providers, coordinating with manufacturers, and more.
Ongoing Patient Support
Our team is dedicated to assisting you with enrollment into a patient assistance program and maintaining access to that program for long-term medication assistance. This includes administrative tasks such as prescription refill support, scheduling, document updates, yearly renewals, program monitoring, and more.
Iqirvo Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Navigating Primary Biliary Cholangitis Treatment Costs
Name-brand prescriptions have a reputation for being incredibly expensive, but there are many prescription access solutions. Normally, there are downsides to each one. Government programs may not help fully with funding for medications. Insurance programs can include high co-pays or deductibles. Coupon or discount cards sometimes only offer limited savings.
Prescription Hope offers help that is unlike any of those options. We are not an insurance company, government-affiliated, or a discount card. We help qualified patients receive access to name-brand medication for the low rate of $70.00 per month, per medication. We do not charge our qualified patients hidden fees, add-ons, or even medication costs.
Patients who do not qualify for a patient assistance program may still be assisted by us. Our team of dedicated staff will work to find you ways to save on your name-brand medication, such as substitute medications, discount cards, or coupons. If we cannot help you find a way to save money, you pay us nothing!
Iqirvo Patient Assistance Eligibility
General Eligibility Requirements
If you are looking to understand Iqirvo patient assistance qualifications, you must first know what the criteria for medication assistance eligibility are. Each program will often set its own requirements, so patients can tell if they are likely to qualify as they are looking for a program for medication assistance.
Here are a couple of categories that programs usually have criteria for:
Income: Each program has a different requirement for a patient’s income status.
Insurance: Each program also has a different requirement for a patient’s insurance coverage.
Prescription: Patients must hold a valid prescription for their intended medication to qualify.
U.S. Residency: Only legal residents of the U.S. can qualify for a patient assistance program.
Simple Enrollment With Expert Support
Getting Started With Enrollment
Looking to enroll in Iqirvo assistance? Does the idea of the Iqirvo application process feel daunting? Are you in need of some prescription support services? Enrollment into Prescription Hope only takes 6 simple steps:
- Submit Information: Our enrollment form can be completed online in just a few minutes.
- Advocate Contact: Following the receipt of your enrollment form, a patient advocate will reach out to you in 1-2 business days.
- Document Collection: Our team will collect all your necessary documents after your prequalification phase.
- Provider Coordination: Our team will also get any vital signatures from your healthcare provider.
- Program Submission: We will submit your application on your behalf and continue to coordinate with the pharmaceutical manufacturer once everything is in order.
- Medication Delivery: Patients will normally receive their medication in the mail in 2 weeks after approval.
Prescription Hope is not a pharmaceutical manufacturer or pharmacy, and does not handle any medication. All medications ship from the pharmaceutical manufacturer to the patient’s door or their healthcare provider’s office.
Understanding Iqirvo
How Iqirvo Works
Iqirvo is a dual peroxisome proliferator-activated receptor alpha (PPAR-α) and peroxisome proliferator-activated receptor delta (PPAR-δ) agonist. These receptors play important roles in regulating bile acid metabolism, inflammation, lipid metabolism, and normal liver cell function.
By activating both PPAR-α and PPAR-δ, Iqirvo helps improve bile acid processing and reduce inflammation within the liver. These effects help decrease liver injury caused by primary biliary cholangitis and improve important biochemical markers associated with liver disease, including alkaline phosphatase (ALP) and total bilirubin.
What Conditions Does Iqirvo Treat?
Iqirvo is FDA-approved for the treatment of primary biliary cholangitis (PBC) in adults.
The medication may be used in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA alone or as monotherapy in adults who are unable to tolerate UDCA.
Iqirvo received FDA Accelerated Approval based on improvements in alkaline phosphatase (ALP) and total bilirubin. Continued approval may depend on verification of clinical benefit in confirmatory clinical trials.
Iqirvo is not recommended for patients who have or develop decompensated cirrhosis, including those with ascites, variceal bleeding, or hepatic encephalopathy.
Benefits of Treatment
For appropriate adults with primary biliary cholangitis, Iqirvo provides an additional treatment option designed to improve important laboratory markers associated with liver health.
Potential benefits include lowering elevated alkaline phosphatase (ALP) levels, improving total bilirubin levels, improving laboratory markers associated with liver function, helping slow the progression of primary biliary cholangitis, providing an additional option when UDCA alone is insufficient, and offering an alternative treatment for patients who cannot tolerate UDCA.
Although Iqirvo has demonstrated meaningful improvements in laboratory markers of liver disease, its long-term effects on liver-related complications, liver transplantation, or overall survival have not yet been established.
Important Safety Information and Side Effects
Iqirvo does not carry an FDA Boxed Warning.
The most commonly reported side effects include weight gain, abdominal pain, diarrhea, nausea, vomiting, muscle pain (myalgia), increased creatine phosphokinase (CPK), bone fractures, gastroesophageal reflux disease (GERD), dry mouth, and rash. Less commonly, patients may experience weight loss or gallbladder-related symptoms. Patients should notify their healthcare provider if side effects become severe or persistent.
Iqirvo may cause drug-induced liver injury and may increase liver enzyme levels or worsen liver function. Healthcare providers should monitor liver tests before treatment begins and periodically throughout therapy. Patients should promptly report yellowing of the skin or eyes, dark urine, severe fatigue, or persistent nausea and vomiting.
Treatment may lead to myopathy or rhabdomyolysis, including serious muscle injury. The risk may be increased in patients taking statins or other medications associated with muscle toxicity. Patients should promptly report muscle pain, tenderness, or weakness. Healthcare providers may monitor creatine phosphokinase (CPK) levels when clinically appropriate.
Bone fractures have been reported during treatment. Patients should discuss bone health and fracture risk with their healthcare provider, particularly if they have additional risk factors for osteoporosis or fractures.
Gallbladder and biliary events, including gallstones and biliary obstruction, have occurred during treatment. Patients should seek prompt medical evaluation if they develop severe upper abdominal pain, fever, or jaundice.
Serious hypersensitivity reactions have been reported. Patients should seek emergency medical attention if they experience swelling of the face, lips, tongue, or throat, difficulty breathing, or a severe rash.
Iqirvo is not recommended for patients with decompensated cirrhosis, as worsening liver function may occur.
Human data regarding Iqirvo use during pregnancy are limited. Patients who are pregnant or planning to become pregnant should discuss the potential benefits and risks of treatment with their healthcare provider. It is unknown whether elafibranor passes into human breast milk. Patients should discuss breastfeeding plans with their healthcare provider before beginning treatment.
Healthcare providers should review all medications before treatment because clinically significant drug interactions may occur. Potential interactions include bile acid sequestrants, which may decrease elafibranor absorption; estrogen-containing hormonal contraceptives and hormone replacement therapies; statins and other medications associated with muscle toxicity; and medications that affect liver function. Patients should provide a complete list of prescription medications, over-the-counter medications, vitamins, and herbal supplements before beginning therapy.
Iqirvo is taken orally once daily and may be taken with or without food. It may be used either alone or in combination with UDCA depending on the patient’s treatment plan and tolerance. Treatment should continue unless otherwise directed by the healthcare provider managing primary biliary cholangitis.
Healthcare providers typically monitor liver function tests, total bilirubin, alkaline phosphatase (ALP), creatine phosphokinase (CPK) when muscle symptoms occur, and signs of gallbladder or biliary complications throughout treatment.
Access to Multiple Medications
Support Beyond Iqirvo
Some patients undergoing treatment for liver disease are also looking for multiple medication assistance programs due to the severity of their condition. Prescription Hope is proud to offer access to hundreds of brand-name medications and their associated patient assistance programs for the low monthly rate of $70.00 per month, per medication. Our specialty medication is here for you, no matter how many medications you qualify for.
Why Choose Prescription Hope for Iqirvo Assistance
Patient-Focused Medication Support
For two decades, Prescription Hope has helped Americans across the country have access to the medications they need at a lower cost than market rate. Our team of medication access specialists provides patient-centered assistance, which is not limited to Iqirvo assistance through Prescription Hope.
Simplified Access to Specialty Medications
Prescription Hope is committed to helping you obtain prescription assistance help. We help find treatment affordability solutions for just $70.00 per month, per medication. That price comes along with the guarantee of no add-ons, hidden charges, or medication costs. If we cannot help you save money while paying for your name-brand medication, you pay us nothing!
Ongoing Prescription Assistance
We don’t just help you find affordable Iqirvo access. We are committed to helping you maintain prescription affordability programs that work for you, which is why we help you with administrative tasks related to your patient assistance program as long as you are a patient with us. These administrative tasks look like refill scheduling, yearly renewals, document updates, program monitoring, and more.
Network Access
We are proud to say that our network reaches from sea to shining sea, allowing American patients the ability to get their needed name-brand medications anywhere from the city to rural areas.
If you want to apply for the Iqirvo Patient Assistance Program and you’re not sure where to start, enroll with Prescription Hope to see how we can help you save money today!